Alemtuzumab in solid organ transplantation and in composite tissue allotransplantation

作者：Weissenbasher Annemarie; Boesmueller Claudia; Brandacher Gerald; Pratschke Robert; Pratschke Johann; Schneeberger Stefan^*

来源：Immunotherapy, 2010, 2(6): 783-790.

DOI：10.2217/IMT.10.68

• alemtuzumab
• campath-1H
• composite tissue
• monoclonal antibody
• transplantation

Alemtuzumab (Campath (R), Genzyme Corporation, MA, USA) is a potent monoclonal antilymphocyte, anti-CD52 antibody. Since the 1980s, alemtuzumab has been used extensively in organ transplantation as an induction agent also with the aim of avoiding or reducing maintenance immunosuppression. We herein review the literature on alemtuzumab in solid organ and composite tissue allotransplantation with an emphasis on clinical and mechanistic aspects of alemtuzumab. In summary, the use of alemtuzumab in solid organ and composite tissue allotransplantation shows excellent early results and holds potential for wider use in conjunction with immunosuppression minimization protocols.

• 出版日期2010-11